Press Releases April 8, 2026 08:30 AM

Verisk to Announce Fiscal First-Quarter 2026 Results on April 29, 2026

Verisk schedules fiscal Q1 2026 earnings release and webcast for April 29, 2026

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
VRSK

Verisk, a Nasdaq-listed global strategic data analytics and technology company serving the insurance industry, announced it will report its fiscal first-quarter 2026 results on April 29, 2026, before the market opens. Management will host a live audio webcast to discuss financial results and business highlights during the morning of the same day. The webcast and a replay will be available on Verisk's investor website.

Verisk to Announce Fiscal First-Quarter 2026 Results on April 29, 2026
VRSK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Verisk is releasing fiscal Q1 2026 results on April 29, 2026, accompanied by a live webcast with management commentary.
  • The company specializes in data analytics and technology solutions for the global insurance industry, addressing underwriting, claims, fraud, and global risk issues such as climate change and sustainability.
  • Verisk operates globally with presence in over 20 countries and is recognized as a Great Place to Work, underscoring corporate culture and operational scale.

JERSEY CITY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, will report its financial results for the fiscal first quarter ended March 31, 2026, on Wednesday, April 29, 2026, before the market open. The press release, with accompanying financial information, will be posted on the Verisk investor website at http://investor.verisk.com.

Verisk’s management team will host a live audio webcast to discuss the financial results and business highlights on Wednesday, April 29 at 8:30 a.m. ET. All interested parties are invited to listen to the live event via webcast on the Verisk investor website at http://investor.verisk.com. The discussion will also be available through dial-in number 1-833-461-5787 for U.S. participants, 1-365-657-4048 for Canada participants or 1-44-808-196-8935 for UK participants.

A replay of the webcast will be available for up to one year on the Verisk investor website.

About Verisk 

Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, catastrophic events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work. For more, visit Verisk.com.


Risks

  • Financial results may be impacted by risks inherent to the insurance analytics sector, including changes in global risk factors like climate and political issues.
  • Market reaction could be influenced by the company’s ability to meet or exceed analyst expectations in a competitive technology and data analytics environment.
  • External economic conditions and industry-specific challenges could affect Verisk’s revenue growth and operational performance conveyed in the upcoming earnings report.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026